Mikkael Sekeres
Chief, Division of Hematology , Hematology · University of Miami/Jackson Health System
Credentials: · · · · ·
History
- Present
Division of Hematology · University of Miami/Jackson Health System
Research
Revised international prognostic scoring system for myelodysplastic syndromes
Blood · 2012 · 2,603 citations
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
Blood · 2015 · 1,615 citations
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
New England Journal of Medicine · 2018 · 1,234 citations
158 papers
- RK
108 papers
70 papers
69 papers
- AL
65 papers
- AD
65 papers
65 papers
62 papers · 55 as a resident
Grants
- 2006–2007
General Clinical Research Center
National Center for Research Resources · M01
Project lead · $5.5K · Cleveland Clinic Lerner Com-Cwru
Clinical trials
- 2021–2029
Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients
Principal investigator · Suspended · Phase 1, Phase 2
Mikkael Sekeres, MD
- 2012–2027
Principal investigator · Active not recruiting · Phase 2
National Cancer Institute (NCI)
- 2016–2025
The National Myelodysplastic Syndromes (MDS) Study
Study chair · Completed
National Heart, Lung, and Blood Institute (NHLBI)
- 2006–2011
Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes
Study chair · Completed · Phase 1, Phase 2
Mikkael Sekeres MD